GlassScriptPhysician profile
Jeanny Riley
NPI 1528733425
$9,145.26
in general payments reported to CMS, 2019-2025
42 companies · $1,853 in 2025
The $1,853 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $631 · 2022: $2,518 · 2023: $1,695 · 2024: $2,449 · 2025: $1,853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,959 · Education: $37.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,959.42 |
| Education | $37.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,748.76 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,356.19 | 2021-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $966.16 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Genzyme Corporation | $487.53 | 2022-2025 | |
| Ardelyx, INC. | $469.36 | 2022-2025 | Ibsrela |
| Gilead Sciences, INC. | $447.67 | 2021-2025 | |
| Qol Medical, LLC | $348.51 | 2023-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $334.80 | 2022-2025 | Dupixent |
| Janssen Biotech, INC. | $328.82 | 2022-2025 | Stelara, Tremfya |
| Celgene Corporation | $282.62 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $207.29 | 2021-2024 | Linzess |
| Pfizer INC. | $195.33 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $191.98 | 2024-2025 | Zenpep, Vowst |
| Merck Sharp & Dohme LLC | $181.17 | 2023-2024 | Keytruda, Dificid |
| Evoke Pharma, INC. | $179.72 | 2021-2025 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $177.83 | 2024-2025 | Iqirvo |
| Madrigal Pharmaceuticals | $166.30 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $141.02 | 2024-2025 | Omvoh |
| Nestle Healthcare Nutrition INC. | $122.68 | 2022-2023 | |
| Celltrion USA INC. | $74.12 | 2024-2025 | Zymfentra, Vegzelma |
| Intercept Pharmaceuticals, INC. | $73.33 | 2021-2024 | Ocaliva |
| Shield Therapeutics INC | $58.45 | 2023-2025 | Accrufer |
| Redhill Biopharma INC. | $55.46 | 2021 | |
| Exact Sciences Corporation | $50.05 | 2023-2024 | Cologuard Collection Kit |
| Fresenius Kabi USA, LLC | $47.90 | 2023-2024 | Idacio |
| Amgen INC. | $46.46 | 2024-2025 | Uplizna |
| Phathom Pharmaceuticals, INC. | $46.44 | 2024-2025 | Voquezna |
| Organon LLC | $43.94 | 2023-2024 | Renflexis |
| Braintree Laboratories, INC. | $42.74 | 2022 | |
| Novo Nordisk INC | $41.34 | 2025 | Wegovy |
| Mallinckrodt Hospital Products INC. | $29.96 | 2024 | Terlivaz |
| Neurocrine Biosciences, INC. | $25.88 | 2022 | |
| Enterra Medical, INC. | $23.69 | 2024 | |
| Janssen Scientific Affairs, LLC | $23.46 | 2024 | Stelara |
| Daiichi Sankyo INC. | $19.36 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.90 | 2022 | |
| Biocon Biologics INC | $16.64 | 2025 | Yesintek |
| Axonics, INC. | $16.55 | 2024 | Axonics |
| Intra-Sana Laboratories | $15.65 | 2022 | |
| Tersera Therapeutics LLC | $14.92 | 2022 | |
| Ferring Pharmaceuticals INC. | $14.16 | 2025 | Rebyota |
| Alfasigma USA, INC. | $14.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeanny Riley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.